Pasquali S, et al. - Researchers investigated the benefits of providing adjuvant chemotherapy in patients with high-risk soft tissue sarcoma (STS), as identified using the nomogram Sarculator, in the EORTC-STBSG 62931 randomized controlled trial (RCT), which failed to detect an impact for adjuvant doxorubicin plus ifosfamide (Adj) over observation (Obs). They analyzed patients with extremity and trunk wall STS in the EORTC-STBSG 62931 RCT (N = 290/351). Outcomes suggest achievement of better outcomes in patients of the EORTC-STBSG 62931 RCT with extremity and trunk wall STS and a low predicted probability of overall survival (high-risk patients) when treated with adjuvant chemotherapy. This may assist in reconciling the different outcomes of clinical studies on adjuvant/neoadjuvant chemotherapy in STS.